Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis

被引:47
作者
Banerjee, Souvik [1 ]
Hwang, Dong-Jin [1 ]
Li, Wei [1 ]
Miller, Duane D. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, 881 Madison Ave, Memphis, TN 38163 USA
关键词
tubulin dynamics; tubulin inhibitors; multidrug resistance; nanoparticle formulations; beta-tubulin isotypes and drug resistance; angiogenesis; vascular disrupting agent; antimitotic; PHASE-I TRIAL; SERUM-ALBUMIN NANOPARTICLES; ENDOTHELIAL-CELL MIGRATION; BOUND NAB PACLITAXEL; TESTING STAGE 1; TUMOR-VASCULATURE; TRASTUZUMAB-EMTANSINE; BIOLOGICAL EVALUATION; POLYMERIZATION INHIBITOR; ANTIANGIOGENIC ACTIVITY;
D O I
10.3390/molecules21111468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extensive research over the last decade has resulted in a number of highly potent tubulin polymerization inhibitors acting either as microtubule stabilizing agents (MSAs) or microtubule destabilizing agents (MDAs). These inhibitors have potent cytotoxicity against a broad spectrum of human tumor cell lines. In addition to cytotoxicity, a number of these tubulin inhibitors have exhibited abilities to inhibit formation of new blood vessels as well as disrupt existing blood vessels. Tubulin inhibitors as a vascular disrupting agents (VDAs), mainly from the MDA family, induce rapid tumor vessel occlusion and massive tumor necrosis. Thus, tubulin inhibitors have become increasingly popular in the field of tumor vasculature. However, their pharmaceutical application is halted by a number of limitations including poor solubility and toxicity. Thus, recently, there has been considerable interests in the nanoparticle drug delivery of tubulin inhibitors to circumvent those limitations. This article reviews recent advances in nanoparticle based drug delivery for tubulin inhibitors as well as their tumor vasculature disruption properties.
引用
收藏
页数:19
相关论文
共 120 条
[1]  
[Anonymous], 2014, J CANC SCI THER, DOI DOI 10.4172/1948-5956.1000277
[2]   Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung [J].
Athawale, Rajani B. ;
Jain, Darshana S. ;
Singh, Kamlinder K. ;
Gude, Rajiv P. .
BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (02) :231-240
[3]   Design, Synthesis and Biological Evaluation of Novel 5H-Chromenopyridines as Potential Anti-Cancer Agents [J].
Banerjee, Souvik ;
Wang, Jin ;
Pfeffer, Susan ;
Ma, Dejian ;
Pfeffer, Lawrence M. ;
Patil, Shivaputra A. ;
Li, Wei ;
Miller, Duane D. .
MOLECULES, 2015, 20 (09) :17152-17165
[4]   Design and development of paclitaxel-loaded bovine serum albumin nanoparticles for brain targeting [J].
Bansal, Amit ;
Kapoor, Deepak N. ;
Kapil, Rishi ;
Chhabra, Neha ;
Dhawan, Sanju .
ACTA PHARMACEUTICA, 2011, 61 (02) :141-156
[5]  
Bighin C, 2013, FUTURE ONCOL, V9, P955, DOI [10.2217/fon.13.74, 10.2217/FON.13.74]
[6]   The pharmacological bases of the antiangiogenic activity of paclitaxel [J].
Bocci, Guido ;
Di Paolo, Antonello ;
Danesi, Romano .
ANGIOGENESIS, 2013, 16 (03) :481-492
[7]   Combretastatin A-4 Conjugated Antiangiogenic Micellar Drug Delivery Systems Using Dendron-Polymer Conjugates [J].
Bolu, Burcu Sumer ;
Gecici, Ece Manavoglu ;
Sanyal, Rana .
MOLECULAR PHARMACEUTICS, 2016, 13 (05) :1482-1490
[8]   MECHANISM OF ACTION OF COLCHICINE - BINDING OF COLCHINCINE-3H TO CELLULAR PROTEIN [J].
BORISY, GG ;
TAYLOR, EW .
JOURNAL OF CELL BIOLOGY, 1967, 34 (02) :525-&
[9]   Combined Treatment Strategies for Microtubule Stabilizing Agent-Resistant Tumors [J].
Broggini-Tenzer, Angela ;
Sharma, Ashish ;
Nytko, Katarzyna J. ;
Bender, Sabine ;
Vuong, Van ;
Orlowski, Katrin ;
Hug, Daniel ;
O'Reilly, Terence ;
Pruschy, Martin .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (04)
[10]   The contribution of αβ-tubulin curvature to microtubule dynamics [J].
Brouhard, Gary J. ;
Rice, Luke M. .
JOURNAL OF CELL BIOLOGY, 2014, 207 (03) :323-334